ArticleTherapeutic advances in drug safety2018
Poly-de-prescribing to treat polypharmacy: efficacy and safety.
Article in Therapeutic advances in drug safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Applying the Bradford Hill Criteria to Assess the Independent Causal Roles of Aging and Medication in Frailty Progression: A Systematic Review.Drugs & aging · 2026Pooled it
- Deprescribing in palliative patients with cancer: a concise review of tools and guidelines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- A systematic review of the evidence for deprescribing interventions among older people living with frailty.BMC geriatrics · 2021Pooled it
- Trial
- The OptimaMed intervention to reduce medication burden in nursing home residents with severe dementia: results from a pragmatic, controlled study.BMC geriatrics · 2023Trial
- Recommendations for the management of frailty in chronic kidney disease: a consensus report.Nature reviews. Nephrology · 2026Review
- Editorial: Optimizing medication management in older adults: addressing polypharmacy, deprescribing and represcribing challenges.Frontiers in medicine · 2026Article
- Article
- Antihypertensive Deprescribing and Functional Status in VA Long-Term Care Residents With and Without Dementia.Journal of the American Geriatrics Society · 2025Article
- Article
- Sleep Quality and Medication Adherence in Older Adults: A Systematic Review.Clocks & sleep · 2024Review
- Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist's geriatric assessment.Scientific reports · 2024Article
- Optimizing clinical outcomes in polypharmacy through poly-de-prescribing: a longitudinal study.Frontiers in medicine · 2024Article
- Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks.Current Alzheimer research · 2024Review
- Deprescribing: A Prime Opportunity to Optimize Care of Cancer Patients.Current oncology (Toronto, Ont.) · 2023Review
- Intervention design in cognitively impaired populations-Lessons learned from the OPTIMIZE deprescribing pragmatic trial.Journal of the American Geriatrics Society · 2023Article
- Polypharmacy, potentially inappropriate medications and associated factors among older adults with hypertension in primary care.Revista brasileira de enfermagem · 2023Article
- Epidemiology of adverse drug events and medication errors in four nursing homes in Japan: the Japan Adverse Drug Events (JADE) Study.BMJ quality & safety · 2022Article
- Developing a core outcome set for hospital deprescribing trials for older people under the care of a geriatrician.Age and ageing · 2022Article
- Development of a deprescribing manual for frail older people for use in the COFRAIL study and in primary care.Therapeutic advances in drug safety · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to evaluate efficacy and safety of poly-de-prescribing (PDP) based on the Garfinkel method in older people with polypharmacy.
methodsA longitudinal, prospective, nonrandomized study in Israel was carried out between 2009 and 2016. Comprehensive geriatric assessments were performed at home in people age ⩾66 years consuming ⩾6 prescription drugs. Exclusion criteria were life expectancy <6 months and a seeming unwillingness to cooperate (poor compliance). PDP of ⩾3 prescription drugs was recommended. Follow up was at ⩾3 years. Between April 2015 and April 2016 Likert scale questionnaires were filled by all participants/families to evaluate overall satisfaction and clinical outcomes. The outcome measures were change in functional, mental and cognitive status, sleep quality, appetite, continence; major complication, hospitalizations, mortality, and family doctor's cooperation.
resultsPoly-de-prescribing of ⩾3 drugs was eventually achieved by 122 participants (PDP group); ⩽2 drugs stopped by 55 'nonresponders' (NR group). The average age was 83.4 ± 5.3 in the PDP group, and 80.8 ± 6.3 in the NR group (
conclusionsThis self-selected sample longitudinal research strongly suggests that the negative, usually invisible effects of polypharmacy are reversible. PDP is well tolerated and associated with improved clinical outcomes, in comparison with outcomes of older people who adhere to all clinical guidelines and take all medications conventionally. Future double-blind studies will probably prove beneficial economic outcomes as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.